What changed: Neuroblastoma (paediatric)
Every dated change on the records linked to Neuroblastoma (paediatric), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2026 · 4
- 2026GuidelineNeuroblastoma (paediatric)Guideline 2026: High risk: consolidation
Tandem autologous transplant (thiotepa-cyclophosphamide, then CEM) in North America (ANBL0532); single busulfan-melphalan transplant in Europe (HR-NBL1). (NCCN COG standard (tandem); SIOPEN standard (BuMel))
- 2026GuidelineNeuroblastoma (paediatric)Guideline 2026: High risk: post-consolidation
Anti-GD2 antibody (dinutuximab + GM-CSF + isotretinoin; dinutuximab beta in Europe, no IL-2) × 5-6 cycles; then eflornithine maintenance 2 years (US, 2023). (NCCN Dinutuximab: FDA-approved standard; eflornithine: FDA-approved maintenance)
- 2026GuidelineNeuroblastoma (paediatric)Guideline COG 2026: High risk: induction
5-6 cycles (COG: topotecan-cyclophosphamide × 2 then cisplatin-etoposide, cyclophosphamide-doxorubicin-vincristine; SIOPEN: rapid COJEC); stem-cell harvest; ANBL1531 adds 131I-MIBG (randomised) or lorlatinib (ALK); ANBL17P1 adds dinutuximab to induction. (NCCN COG ANBL1531 backbone)
- 2026MilestoneCOG ANBL1531ANBL1531 MIBG randomisation maturing; ALK arm reports
A milestone in how this cancer is treated.
2025 · 1
2023 · 2
2020 · 1
2019 · 1
2017 · 1
2015 · 1
2010 · 2
2009 · 1
2008 · 2
- 2008ApprovalIobenguane I-123Iobenguane I-123 approved in US
Detection of primary or metastatic pheochromocytoma or neuroblastoma as an adjunct to other diagnostic tests
- 2008MilestoneNeuroblastoma (paediatric)ALK mutations identified as a hereditary and somatic driver
A milestone in how this cancer is treated.